UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 175 filers reported holding UNIQURE NV in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $277,640 | -59.6% | 41,377 | -31.0% | 0.01% | -61.1% |
| Q2 2023 | $687,600 | +43.0% | 60,000 | +284.0% | 0.02% | -56.1% |
| Q2 2021 | $481,000 | +26.6% | 15,626 | +48.5% | 0.04% | +2.5% |
| Q4 2020 | $380,000 | +47.9% | 10,524 | +94.6% | 0.04% | +110.5% |
| Q1 2020 | $257,000 | -47.8% | 5,409 | -56.7% | 0.02% | -54.8% |
| Q3 2019 | $492,000 | +2.3% | 12,502 | +103.0% | 0.04% | -2.3% |
| Q2 2019 | $481,000 | -75.4% | 6,158 | -81.2% | 0.04% | -69.1% |
| Q1 2019 | $1,955,000 | +618.8% | 32,772 | +354.7% | 0.14% | +631.6% |
| Q2 2018 | $272,000 | +202.2% | 7,208 | -55.2% | 0.02% | +35.7% |
| Q4 2016 | $90,000 | -84.7% | 16,080 | -79.9% | 0.01% | -81.8% |
| Q2 2016 | $589,000 | +44.7% | 79,968 | +133.5% | 0.08% | +60.4% |
| Q1 2016 | $407,000 | +83.3% | 34,254 | +214.2% | 0.05% | +152.6% |
| Q3 2015 | $222,000 | -73.1% | 10,903 | -64.4% | 0.02% | -79.6% |
| Q2 2015 | $826,000 | +284.2% | 30,600 | +245.1% | 0.09% | +322.7% |
| Q1 2015 | $215,000 | – | 8,868 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |